Bank of America
INDV icon

Bank of America’s Indivior Pharmaceuticals INDV Stock Holding History

Bank of America’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,300
Closed -$79.6K – 7833
2025
Q3 		$79.6K Buy
+3,300
New +$69.1K ﹤0.01% 6683

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America's INDV Position: Q1 2026 in Review

Bank of America reduced its Indivior Pharmaceuticals (INDV) stake by 17% in Q1 2026, selling an estimated $4.53M and leaving 667,132 shares worth $20.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2378.

Bank of America first reported a position in INDV in Q2 2023 and has held it in 12 quarters since. The position peaked at $65.5M in Q2 2024. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Bank of America held 667,132 shares of Indivior Pharmaceuticals worth $20.3M as of Q1 2026.
  • Bank of America sold 137,103 Indivior Pharmaceuticals shares in Q1 2026, an estimated $4.53M.
  • Indivior Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2378 holding.
  • Bank of America first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • Bank of America's Indivior Pharmaceuticals position peaked at $65.5M in Q2 2024.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.